Site Title Goes Here

Shortcut Navigation:

ACT FOR CHANGE

The CARE Act would ensure proper training for lab technicians who administer radiation-based medical screening and therapies.

TAKE ACTION

VICTORIES

victory_ab929
Medical Radiation Safety in California

A medical radiation safety law in California ensures that patients receive the lowest dose possible without compromising image quality.

LEARN MORE >

STRONG VOICES

Janet Gray, Ph.D.
Janet Gray, Ph.D.

As author of our 2008 and 2010 State of the Evidence reports, Dr. Gray drives the science behind all our work.

LEARN MORE >
Printer Friendly

Diethylstilbestrol (DES)

CATEGORY*: IARC known, NTP known

FOUND IN: Prescribed to pregnant women between 1938 and 1971 to prevent miscarriage

THE GIST: Between 1938 and 1971 doctors prescribed DES for millions of pregnant women to prevent miscarriages, culminating in a medical tragedy that has affected at least 5 million people. Daughters of women who took the drug were found to have higher rates of an extremely rare vaginal cancer, in addition to breast cancer. The drug was banned in 1971.

State of the Evidence on Diethylstilbestrol (DES)

The clearest evidence that a synthetic estrogen can increase risk for cancer decades later comes from the tragic experience with diethylstilbestrol (DES).

TIPS FOR PREVENTION

We must ensure that chemicals that behave like DES do not make their way into our food or other products.

Join the Breast Cancer Fund in advocating for responsible chemical regulations>

Between 1938 and 1971, doctors prescribed DES for millions of pregnant women to prevent miscarriages. The drug was banned when daughters of women who took the drug were found to have higher rates of an extremely rare vaginal cancer than women who were not exposed to DES in the womb (Bibbo 1977; Herbst, 1970). DES exposure is also associated with an increased risk of breast cancer in the women who took it during the 1950s (Colton, 1993; Titus-Ernstoff, 2001).

In a follow-up study of daughters who were exposed prenatally to DES, a nearly twofold increase in breast cancer risk was observed in women older than age 40. An even greater effect was found for women over the age of 50, although relatively few of the daughters had yet reached that age at the time of the study (Palmer, 2006; Troisi, 2007). Women exposed in utero who had the most severe abnormalities of their vaginal epithelial cells (an indicator of exposures to higher doses of DES) also had a higher risk for developing breast cancer (Hoover, 2011).

Studies examining the mechanisms by which DES might be exerting its carcinogenic effects indicate that the compound activates the same subcellular pathways as estradiol. They both act through altering cellular metabolism and through interactions with DNA (Saeed, 2009), and increase the rate of breast-cell proliferation (Larson, 2006).

*For chemicals that have been shown to be carcinogens, we provide classifications from two authoritative bodies: the International Agency for Research on Cancer (IARC, an international body) and the National Toxicology Program (NTP, a division of the U.S. Department of Health and Human Services). We have categorized endocrine-disrupting compounds where the body of peer-reviewed research indicates a strong foundation for doing so.